Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination

Muktha S. Natrajan, Alerie Guzman de la Fuente, Abbe Crawford, Eimear Linehan, Vanessa Núñez, Kory R. Johnson, Tianxia Wu, Denise Fitzgerald, Mercedes Ricote, Bibiana Bielekova,

Brain · 2015 · 216 citations · 239 references

DOIFull text

Open access

Concepts

Abstract

The efficiency of central nervous system remyelination declines with age. This is in part due to an age-associated decline in the phagocytic removal of myelin debris, which contains inhibitors of oligodendrocyte progenitor cell differentiation. In this study, we show that expression of genes involved in the retinoid X receptor pathway are decreased with ageing in both myelin-phagocytosing human monocytes and mouse macrophages using a combination of in vivo and in vitro approaches. Disruption of retinoid X receptor function in young macrophages, using the antagonist HX531, mimics ageing by reducing myelin debris uptake. Macrophage-specific RXRα (Rxra) knockout mice revealed that loss of function in young mice caused delayed myelin debris uptake and slowed remyelination after experimentally-induced demyelination. Alternatively, retinoid X receptor agonists partially restored myelin debris phagocytosis in aged macrophages. The agonist bexarotene, when used in concentrations achievable in human subjects, caused a reversion of the gene expression profile in multiple sclerosis patient monocytes to a more youthful profile and enhanced myelin debris phagocytosis by patient cells. These results reveal the retinoid X receptor pathway as a positive regulator of myelin debris clearance and a key player in the age-related decline in remyelination that may be targeted by available or newly-developed therapeutics. Ageing impairs CNS remyelination, partially through impaired phagocytosis of myelin debris, which contains inhibitors of oligodendrocyte progenitor cell differentiation. Natrajan et al. identify retinoid X receptor (RXR) signalling as a genetic and pharmacological target to reverse this impairment, and successfully enhance myelin phagocytosis in monocytes from patients with multiple sclerosis.

References

239